

Contents

Foreword	9
1. BASIC CHARACTERISTICS OF HAEMOPHILIA	11
1.1. What is Haemophilia?	13
1.2. Historical Data	13
1.3. Epidemiology	14
1.4. Pathophysiology of the Disease	15
1.5. Haemophilia A	16
1.6. Haemophilia B	17
1.7. Inheritance of Haemophilia	18
1.8. Carriers of Haemophilia	19
2. SPECIFICITIES OF HAEMOPHILIA	21
2.1. Classification of Haemophilia	23
2.2. Clinical Features of Haemophilia	24
2.2.1. Bleeding into the Joint	25
2.2.2. Pathogenesis of Haemophilic Arthropathy	25
2.2.3. Mucosal Bleeding	27
2.2.4. Muscle Bleeding	27
2.2.5. Bleeding into the Central Nervous System	28
2.2.6. Bleedings from the Digestive System, Urogenital System and other Localizations in the Body	29
2.2.7. Bleeding in Early Childhood	29
2.3. Diagnosis of Haemophilia	30
2.3.1. Laboratory Diagnostics of Haemophilia	31
3. TREATMENT OF HAEMOPHILIA	33
3.1. Drugs for Stopping and Preventing Bleeding in Haemophilia (Haemostatic Drugs)	35
3.1.1. Concentrates of Factor VIII/IX of Standard Half-life (SHL) or Shorter Elimination Half-life	37
3.1.2. Concentrates of Extended Half-life Coagulation Factors (EHL)	37
3.1.3. Bypassing Agents	38
3.1.4. Recombinant Activated Factor VIIa (rFVIIa)	38
3.1.5. Activated Prothrombin Complex Concentrate (aPCC)	39
3.1.6. New Therapies for Haemophilia	40

3.2. Pharmacological Therapies in Haemophilia	41
3.2.1. Desmopressin (DDAVP).	41
3.2.2. Tranexamic Acid	42
3.2.3. Epsilon-aminocaproic Acid.	42
3.3. Two Basic Treatments of Haemophilia: On Demand (Episodic) Treatment and Prophylactic Treatment	43
3.3.1. Episodic Treatment of Haemophilia	43
3.3.2. Prophylactic Treatment of Haemophilia	43
3.3.3. Home Treatment	45
3.4. Treatment of Acute Bleeding	45
3.5. Pain Treatment	46
3.6. Gene Therapy in Haemophilia	47
4. COMPLICATIONS IN HAEMOPHILIA	49
4.1. Inhibitors.	51
4.2. Venous Thrombosis	54
4.3. Anaphylaxis	55
4.4. Immunological Modulation	55
4.5. Infections	55
4.6. Damage to the Musculoskeletal System	56
4.7. Pseudotumours	56
4.8. Fractures	56
4.9. Pain	57
5. RESEARCH METHOD	59
5.1. Sample, Time Frame and Circumstances in which the Survey Was Carried Out	61
5.2. Overview and Interpretation of Results	62
6. RESULTS.	63
6.1. Sociodemographic Characteristics	65
6.2. Health Status	68
6.2.1. Basic Information about Haemophilia	68
6.2.2. Therapeutic Options and Treatment	70
6.2.3. Novel Therapies.	77
6.2.4. Bleeding and Pain	78
6.2.5. Comorbidities and Joint Damage	81
6.2.6. Mobility and Anthropometric Features.	86
6.2.7. Dental Status	88
6.2.8. Nutritional Habits, Dietary Supplements and Intoxicants.	90
6.2.9. Coping with the Disease.	92
6.3. Daily Functioning and Socio-psychological Status	93

6.3.1. Social Functioning and Support	93
6.3.2. Religiosity	99
6.3.3. Leisure Time and Restrictions of Daily Activities	101
6.3.4. Sexuality	103
6.3.5. Personal Well-being and Life Satisfaction	104
6.3.6. Psycho-social Imprint of Haemophilia and Psychological Well-being	107
6.3.7. Use of Media	113
6.3.8. Attitudes and Orientations	116
6.3.9. COVID-19 and Earthquakes	117
7. TABLE OVERVIEW OF RESULTS	121
7.1. Sociodemographic Characteristics	123
7.2. Health Status	127
7.2.1. Basic Information about Haemophilia	127
7.2.2. Therapeutic Options and Treatment	128
7.2.3. Novel Therapies	132
7.2.4. Bleeding and Pain	133
7.2.5. Comorbidities and Joint Damage	135
7.2.6. Mobility and Anthropometric Features	140
7.2.7. Dental Status	142
7.2.8. Nutritional Habits, Dietary Supplements and Intoxicants	143
7.2.9. Coping with the Disease	146
7.3. Daily Functioning and Socio-psychological Status	147
7.3.1. Social Functioning and Support	147
7.3.2. Religiosity	151
7.3.3. Leisure Time and Restrictions of Daily Activities	153
7.3.4. Sexuality	154
7.3.5. Personal Well-being and Life Satisfaction	156
7.3.6. The Psycho-social Imprint of Haemophilia and Psychological Well-being	159
7.3.7. Use of Media	164
7.3.8. Attitudes and Orientations	168
7.3.9. COVID-19 and Earthquakes	169
8. SUMMARY OF MAIN FINDINGS	173
8.1. Sociodemographic Characteristics: Structure of the Realised Sample	175
8.2. Health Status	176
8.2.1. Basic Data on Haemophilia	176
8.2.2. Therapeutic Options and Treatment	176
8.2.3. Novel Therapies	178
8.2.4. Bleeding and Pain	178
8.2.5. Comorbidities and Joint Damage	179
8.2.6. Mobility and Anthropometric Characteristics	180
8.2.7. Dietary Habits, Food Supplements and Intoxicants	180
8.2.8. Coping with the Disease	181
8.3. Daily Functioning and Socio-psychological Status	181
8.3.1. Social Functioning and Support	181

8.3.2. Leisure Time and Restrictions of Daily Activities	182
8.3.3. Personal Well-being and Satisfaction with Life	182
8.3.4. Psycho-social Imprint of Haemophilia and Psychological Well-being	183
8.3.5. Use of Media	184
8.3.6. Attitudes and Orientations	184
8.3.7. Context of the Research: Earthquakes and COVID-19	185
9. SAŽETAK GLAVNIH NALAZA	187
9.1. Sociodemografska obilježja: struktura realiziranog uzorka	189
9.2. Zdravstveni status	189
9.2.1. Osnovni podatci o hemofiliji	189
9.2.2. Terapijske opcije i liječenje	190
9.2.3. Nove terapije	191
9.2.4. Krvarenja i bolovi	192
9.2.5. Komorbiditeti i oštećenja zglobova	192
9.2.6. Mobilnost i antropometrijska obilježja	193
9.2.7. Prehrambene navike, dodaci prehrani i opojna sredstva	194
9.2.8. Nošenje s bolešću	194
9.3. Svakodnevno funkcioniranje i sociopsihološki status	194
9.3.1. Socijalno funkcioniranje i podrška	194
9.3.2. Slobodno vrijeme i ograničenja svakodnevnih aktivnosti	195
9.3.3. Osobno blagostanje i zadovoljstvo životom	196
9.3.4. Psihosocijalni otisak hemofilije i psihološka dobrobit	196
9.3.5. Upotreba medija	197
9.3.6. Stavovi i opredjeljenja	197
9.3.7. Kontekst istraživanja: potresi i COVID-19	198
Bibliography	199
About the Authors	211